BJL
DNLI icon

Brighton Jones LLC’s Denali Therapeutics DNLI Stock Holding History

Brighton Jones LLC’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,878
Closed -$203K – 554
2023
Q2 		$203K Buy
+6,878
New +$193K 0.01% 507

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Brighton Jones LLC's DNLI Position: Q3 2023 in Review

Brighton Jones LLC sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 6,878 shares — an estimated $203K sold.

Brighton Jones LLC first reported a position in DNLI in Q2 2023 and held it in 1 quarter. The position peaked at $203K in Q2 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

  • Brighton Jones LLC reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Brighton Jones LLC sold 6,878 Denali Therapeutics shares in Q3 2023, an estimated $203K.
  • Brighton Jones LLC first reported a position in Denali Therapeutics in Q2 2023 and held it in 1 quarter.
  • Brighton Jones LLC's Denali Therapeutics position peaked at $203K in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Brighton Jones LLC's 13F filing for Q3 2023, filed 26 Oct 2023.